Emerald Health Therapeutics Announces $25 Million Convertible Debenture Unit Financing

VANCOUVER, British Columbia, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald or the Company) (TSXV: EMH; OTCQX: EMHTF) has entered into a binding term sheet with a single Canadian institutional accredited investor (the Investor) under which the Investor has agreed, subject to certain customary conditions, to purchase 2,500 secured convertible debenture units (each, a Convertible Debenture Unit) of the Company at a price of $10,000 per Convertible Debenture Unit (the Issue Price) for gross proceeds of $25,000,000 (the Offering).